Clinical Trials Directory

Trials / Terminated

TerminatedNCT02081729

Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)

Status
Terminated
Phase
Study type
Observational
Enrollment
10 (actual)
Sponsor
Asan Medical Center · Academic / Other
Sex
All
Age
16 Years – 99 Years
Healthy volunteers
Not accepted

Summary

VZV is one of the important opportunistic infection in transplant recipients.Until now, there is no laboratory method to stratify the risk of VZV reactivation after solid organ transplantation. Theoretically, VZV-specific cell-mediate immune response before solid organ transplantation will further categorize the patients into high or low risk of VZV development after solid organ transplantation. The investigators thus evaluate the usefulness of VZV-specific ELISPOT assay in kidney transplant candidates to predict the development of VZV infection after kidney transplantation.

Detailed description

We will develop VZV-specific ELISPOT assay, then perform this assay before transplantation. We will evaluate whether this assay will predict zoster reactivation after transplantation.

Conditions

Timeline

Start date
2014-03-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2014-03-07
Last updated
2018-08-29

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02081729. Inclusion in this directory is not an endorsement.

Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT) (NCT02081729) · Clinical Trials Directory